[
  {
    "ts": null,
    "headline": "Why Does Zimmer Biomet's (ZBH) Innovation Push Coincide With Lowered Growth Guidance?",
    "summary": "Zimmer Biomet Holdings recently reported mixed third-quarter 2025 results, with US$2,001.4 million in sales and US$230.9 million in net income, alongside revised guidance lowering full-year organic revenue growth expectations due to ongoing challenges in international markets. At the same time, the company has taken steps forward in product innovation, gaining FDA Breakthrough Device Designation for its iodine-treated total hip replacement system and acquiring Monogram Technologies to expand...",
    "url": "https://finnhub.io/api/news?id=290f402a3b5a689456669d5063c25400af7bbd15425ebc007663f255c7ac3214",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762668983,
      "headline": "Why Does Zimmer Biomet's (ZBH) Innovation Push Coincide With Lowered Growth Guidance?",
      "id": 137384738,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZBH",
      "source": "Yahoo",
      "summary": "Zimmer Biomet Holdings recently reported mixed third-quarter 2025 results, with US$2,001.4 million in sales and US$230.9 million in net income, alongside revised guidance lowering full-year organic revenue growth expectations due to ongoing challenges in international markets. At the same time, the company has taken steps forward in product innovation, gaining FDA Breakthrough Device Designation for its iodine-treated total hip replacement system and acquiring Monogram Technologies to expand...",
      "url": "https://finnhub.io/api/news?id=290f402a3b5a689456669d5063c25400af7bbd15425ebc007663f255c7ac3214"
    }
  }
]